Niagen Bioscience, Inc Stock Price, News & Analysis

Niagen Bioscience (NASDAQ: NAGE) has announced groundbreaking results from the first-ever peer-reviewed study of nicotinamide riboside (NR) in Werner Syndrome (WS), a rare genetic aging disorder. The 52-week double-blind, placebo-controlled study showed that daily 1,000mg Niagen supplementation increased blood NAD+ levels by 140% and improved cardiovascular and skin health markers in WS patients. The study, published in Aging Cell, demonstrated significant improvements in arterial stiffness, HDL particle size, and wound healing. This research expands Niagen's rare disease portfolio, which includes promising results in Ataxia Telangiectasia (AT), where the company has received FDA Orphan Drug and Rare Pediatric Disease Designations. The study involved nine participants with WS and reported no moderate or severe adverse events, establishing a positive safety profile for NR supplementation in this population.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, announced its participation in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. CEO Rob Fried will engage in a fireside chat on June 9, 2025, from 2:15 PM to 2:50 PM ET. Both CEO Rob Fried and CFO Ozan Pamir will conduct one-on-one meetings with institutional investors during the event. The fireside chat will be available via webcast, with a replay accessible on the company's investor relations website. The company, formerly known as ChromaDex Corp., specializes in nicotinamide adenine dinucleotide (NAD+) research and its applications in healthy aging.

Niagen Bioscience (NASDAQ:NAGE) reported strong Q1 2025 financial results with total net sales of $30.5 million, up 38% year-over-year. The company's flagship product Tru Niagen® generated $21.5 million in sales (up 24% YoY), while Niagen® ingredient sales reached $8.0 million (up 95% YoY). Key financial metrics include a gross margin of 63.4% (up 270 basis points), net income of $5.1 million ($0.07 EPS), and Adjusted EBITDA of $4.9 million. The company increased its 2025 outlook, projecting net sales growth of 20-25% (up from 18%). Recently, Niagen rebranded from its previous name and expanded its NAD+ precursor patent portfolio with a new patent covering nicotinamide riboside salt forms.

Niagen Bioscience (NASDAQ: NAGE) announces significant expansion of its pharmaceutical-grade Niagen® IV therapy, now available in nearly 600 clinics nationwide. The patented nicotinamide riboside (NR) treatment demonstrates superior performance compared to traditional NAD+ IV therapy, offering 75% shorter infusion time and 20% higher NAD+ levels three hours post-infusion. Clinical studies show Niagen IV has better tolerability with fewer side effects compared to NAD+ IV, which often causes headaches, stomach pain, and nausea. The treatment is manufactured in FDA-compliant 503B facilities and is gaining popularity among healthcare providers for its effectiveness in supporting cellular energy, recovery, and brain health. Multiple clinics across the US, including specialized wellness centers and medical institutes, report positive patient outcomes and growing demand for this NAD-boosting intervention.

Niagen Bioscience (NASDAQ: NAGE) has strengthened its scientific leadership by appointing renowned gerontologist Dr. Pinchas Cohen to its Scientific Advisory Board. Dr. Cohen, currently serving as Dean of USC Leonard Davis School of Gerontology, brings expertise in healthy aging and mitochondrial biology research.

As a Distinguished Professor of Gerontology, Medicine, and Biological Sciences, Dr. Cohen is recognized for discovering mitochondrial microproteins including MOTS-c, SHLP, SHMOOSE, and MASL - potential therapeutic targets for aging-related diseases. His impressive portfolio includes over 350 scientific papers and founding roles in the Southern California Aging Research Consortium and two biotech companies.

Dr. Cohen's achievements include the NIH Director's Transformative Research Award and the Glenn Award for Research in Biological Mechanisms of Aging. His appointment aligns with Niagen Bioscience's focus on NAD+ research and healthy aging science, reinforcing the company's commitment to advancing healthspan research through scientific collaboration.

Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will release its Q1 2025 results after market close, followed by an investor conference call at 4:30 p.m. ET.

The earnings conference call will include a discussion of financial results and a general business update. Participants are advised to dial in 10 minutes before the call using the toll-free number +1 888 596 4144 with Conference ID 8584242. A webcast will be available, and a replay can be accessed from 7:30 p.m. ET on May 7 until 11:59 p.m. ET on May 14, 2025, using the replay number +1 800 770 2030.

Niagen Bioscience (NASDAQ: NAGE) has confirmed its operational resilience amid new tariff developments, highlighting that its flagship Niagen® ingredient remains exempt from recent tariffs. The company's primary product, nicotinamide riboside (NR), is manufactured, encapsulated, and bottled entirely in the United States through partner W.R. Grace.

With only a minimal portion of materials sourced internationally, the company's manufacturing costs remain largely protected from global price volatility. In 2024, 24% of the company's revenue came from international sales, with 12% specifically from A.S. Watson in Hong Kong, a duty-free market unaffected by tariffs.

Niagen Bioscience (NASDAQ: NAGE) has confirmed that its operations remain unaffected by recent global tariffs, primarily due to its U.S.-based manufacturing strategy. The company's flagship product Niagen® (patented nicotinamide riboside) is manufactured, encapsulated, and bottled domestically by partner W.R. Grace.

The company's strategic decision to maintain a U.S.-based supply chain has proven beneficial, with only a minimal portion of materials sourced internationally. Additionally, nicotinamide riboside (NR) currently maintains an exempt status from recent tariffs, allowing uninterrupted international operations.

In 2024, 24% of the company's revenue came from international sales, with 12% specifically from A.S. Watson in Hong Kong, a duty-free market unaffected by tariffs. The company expects to maintain current costs, pricing, and product delivery capabilities.

Niagen Bioscience (NASDAQ: NAGE) has secured U.S. Patent 12,252,506 for nicotinamide riboside (NR) salt forms, strengthening its NAD+ precursor intellectual property portfolio. The composition of matter patent, exclusively licensed from Queen's University Belfast, covers various NR salt forms including NR Malate and NR Tartrate, as well as other derivatives.

The patent grants Niagen exclusive rights for different NR salt forms and manufacturing methods until 2034. The company's IP portfolio now includes over 90 patents related to its flagship Niagen® ingredient, positioning it as a leader in NAD+ precursor development. According to CEO Rob Fried, any company developing products using these NR salt forms would infringe on this patent.

The protected salt forms include carboxylic acid, dicarboxylic acid, aminodicarboxylic acid, phosphate, sulfate, carbonate, and carbamate salts for nutritional supplement use. Niagen Bioscience claims to be the only company capable of producing NR and its salt forms at commercial scale without patent violation.